Novocure delivered record quarterly revenue and active patient growth, raised its full-year financial guidance and expanded the commercial reach of Optune Pax with European approval.
Novocure (NASDAQ:NVCR) reported record second-quarter net revenue of $183.6 million, up 16% year over year.
Global active patients receiving TTFields therapy increased 18% to 5,128 across all indications.
The company raised its 2026 revenue guidance to $710 million-$725 million and improved its adjusted EBITDA outlook.
Optune Pax received CE Mark approval for locally advanced pancreatic cancer, with Germany becoming the first European launch market.

#year #million #record #raised